Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

DeCarlo Law, P.A., Comments on Report about Weight Loss Drug Contrave


News provided by

Big Voodoo Interactive

Oct 06, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX


Miami, FL (PRWEB) October 06, 2014 -- The Food & Drug Administration (FDA) recently approved the use of the drug Contrave to treat obesity, a decision that also included several warnings about possible dangerous side effects associated with the drug that people need to take seriously, according to drug injury lawyer Jeffrey D. DeCarlo, P.A.

DeCarlo made his comments in response to a recent article published by Healthline about the FDA’s approval of Contrave to treat obesity. (Healthline, “FDA Approves Contrave, a New Combination Pill for Obesity,” Sept. 11, 2014)

The FDA has clearly identified many potential risks associated with Contrave. That’s why people need to clearly understand the risks they face when they take this drug.

Post this

“People need to carefully consult with their doctor before taking Contrave,” DeCarlo said. “The FDA has clearly identified many potential risks associated with Contrave. That’s why people need to clearly understand the risks they face when they take this drug. We express this note of caution because our office has worked with many people suffering from dangerous side effects caused by powerful prescription drugs. Injuries caused by drugs approved by the FDA happen far more often than many people might even realize. That’s why it’s important to know the risks before you start taking a drug like Contrave.”

Manufactured by La Jolla, California-based drug company Orexigen Therapeutics, Contrave is a combination of two FDA-approved drugs frequently used to treat addiction: naltrexone and bupropion. According to the Healthline article, “Naltrexone treats alcohol and opioid dependence. Bupropion is used to treat depression and seasonal affective disorder and as an aid to help people quit smoking.”

Contrave contains a boxed warning “to alert doctors and patients to the increased risk of suicidal thoughts and behaviors associated with antidepressant drugs,” the Healthline article states. “The warning also notes that serious neuropsychiatric events have been reported in patients taking bupropion for smoking cessation.”

Such warnings exist because Contrave contains the anti-depression drug buproprion, according to Forbes Magazine. (Forbes, “FDA Approves Contrave Weight Loss Drug From Orexigen And Takeda,” Sept. 10, 2014)

In addition, the Healthline article noted Contrave can “raise blood pressure and heart rate and must not be used in patients with uncontrolled high blood pressure, according to the FDA.”

Contrave has also been found to “cause seizures and is contraindicated in people with seizure disorders,” according to Forbes Magazine.

Such risks illustrate the dangers of drugs approved by the FDA, according to Miami dangerous drug attorney drug injury lawyer Jeffrey D. DeCarlo, P.A.

“Just because the FDA approves a drug for use by the public does not guarantee that it is perfectly safe for everyone to use,” DeCarlo said. “People regularly suffer from serious or life-threatening side effects caused by drugs prescribed by doctors. Sometimes, drug companies fail to rigorously test their drugs. Other times, physicians prescribe a drug that’s not safe for certain people because the doctor did not take the time to carefully evaluate a patient’s health risks. Whatever the reason, you and your family should not have to suffer because of someone else made a mistake. You have rights and our law firm can stand up for them.”

For more information about what to do if you or loved one is suffering from dangerous drug side effects and the legal options available to injury victims, call (877) 572-0065 or visit us online at http://www.decarlolaw.com/contact/

About Jeffrey D. DeCarlo, P.A.

Attorney Jeffrey D. DeCarlo is a nationally recognized pharmaceutical injury lawyer who has protected the rights of injury victims for over 15 years. His office is in Miami, Fla., but he serves clients throughout the State of Florida and the United States. Attorney Jeffrey D. DeCarlo is a member of both the Million Dollar Advocates Forum and Multi-Million Dollar Advocates Forum, reserved for a small percentage of attorneys who have secured multi-million dollar verdicts and settlements. In addition to handling dangerous drug claims, attorney Jeffrey D. DeCarlo accepts cases involving medical malpractice, defective medical devices, car accidents and catastrophic personal injury.

Jeffrey D. DeCarlo, P.A.
4500 Biscayne Blvd #201
Miami, FL 33137
(305) 572-0065
http://www.decarlolaw.com

Jacob M Del Hagen, Big Voodoo Interactive, http://www.bigvoodoo.com, +1 (413) 650-0593, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.